The results showed BD in breast cancer treatment may take actions through affecting AMIT_SERUM_RESPONSE_40_MCF10A, BILD_HRAS_ONCOGENIC_SIGNATURE, and NAGASHIMA_NRG1_SIGNALING_UP pathways and regulation expression of ZFP36, EGR1, and FOS(c-FOS). This evidence concerns the gene FOS and breast carcinoma.